Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

Journal article

BACKGROUND: No randomised study has shown whether stratification of treatment by minimal residual disease (MRD) response improves outcome in children and young people with acute lymphoblastic leukaemia (ALL). We assessed whether children and young people with clinical standard and intermediate-risk ALL who have persistent MRD at the end of induction therapy benefit from augmented post-remission therapy. METHODS: Between Oct 1, 2003, and June 30, 2011, we enrolled eligible patients aged 1-24 y...

Expand abstract

Authors: Vora, A; Goulden, N; Mitchell, C; Hancock, J; Hough, R

• Publication status: Published
• Journal: Lancet. Oncology
• Volume: 15
• Issue: 8
• Pages: 809-818
• Publication date: 2014-07-01
• DOI: 10.1016/s1470-2045(14)70243-8
• EISSN: 1474-5488
• ISSN: 1470-2045
• Language: English
• Keywords: Drug Hypersensitivity; Cytarabine; Humans; Pancreatitis; Vincristine; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Follow-Up Studies; Stomatitis; Infant; Remission Induction; Disease-Free Survival; Antineoplastic Combined Chemotherapy Protocols; Male; Cyclophosphamide; Methotrexate; Survival Rate; Child; Consolidation Chemotherapy; 6-Mercaptopurine; Female; Risk Assessment; Asparaginase; Adolescent; Doxorubicin; Neoplasm, Residual; Mucositis; Child, Preschool; Dexamethasone